neoplasm

By Targets:	ADC Antibody (1) Antibiotic (2) Apoptosis (2) DNA Alkylator/Crosslinker (2) DNA/RNA Synthesis (2) Drug Metabolite (1) EGFR (2) Endogenous Metabolite (1) Fungal (2) Interleukin Related (1) JAK (5) PD-1/PD-L1 (1) Reference Standards (2) STAT (2) TREM receptor (1)
By Research Areas:	Cancer (17) Infection (3) Inflammation/Immunology (1)
Oligonucleotides:	Fillers (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-126573

Trilaurin	Endogenous Metabolite	Cancer
Trilaurin could inhibit the formation of neoplasms initiated by dimethylbenzanthracene (DMBA) and promoted by croton oil .

HY-146186

JAK2 JH2 binder-1	JAK	Cancer
JAK2 JH2 binder-1 (compound 11) is a potent and selective JAK2 JH2 binder, with a K_d of 37.1 nM. JAK2 JH2 binder-1 has the potential for various myeloproliferative neoplasms research .

HY-16398

Pipobroman	DNA Alkylator/Crosslinker DNA/RNA Synthesis	Cancer
Pipobroman is a bromide derivative of piperazine and acts as an alkylating agent. Pipobroman plays its role by inhibiting DNA and RNA polymerase or by reducing pyrimidine nucleotide incorporation into DNA. Pipobroman can be used for the cancer research, including polycythemia vera, myeloproliferative neoplasm, and AML et.al .

HY-124727

ZT55	JAK Apoptosis	Cancer
ZT55 is an orally active and highly-selective JAK2 inhibitor with an IC₅₀ value of 0.031 μM. ZT55 inhibits the proliferation of JAK2 ^V617F-expressing HEL cell lines and induces apoptosis and cycle arrest. ZT-55 also effectively inhibits the growth of HEL xenograft tumours in a mice model. ZT-55 can be used in studies of myeloproliferative neoplasms, polycythemia vera and primary thrombocythemia .

HY-P99348

Ropeginterferon alfa-2b Ropeginterferon alfa-2b-njft; PEG-proline-interferon alpha-2b	Apoptosis	Cancer
Ropeginterferon alfa-2b (Ropeginterferon alfa-2b-njft) is a monopegylated IFN-α that can be used for the research of myeloproliferative neoplasms .

HY-W741181

Epirubicinol Epidoxorubicinol; 4'-Epidoxorubicinol	Drug Metabolite	Cancer
Epirubicinol is a 13-dihydro metabolite of Epirubicin (HY-13624). Epirubicin has activity similar to Doxorubicin (HY-15142A) in a variety of solid neoplasms and haematologic malignancies .

HY-155746

JAK2-IN-9	JAK	Infection Inflammation/Immunology
JAK2-IN-9 (Compound A8) is a selective JAK2 inhibitor (IC₅₀: 5 nM). JAK2-IN-9 inhibits the phosphorylation of JAK2, STAT3, and STAT5. JAK2-IN-9 has metabolic stabilities. JAK2-IN-9 induces apoptosis. JAK2-IN-9 can be used for research of myeloproliferative neoplasms (MPNs) .

HY-174988

JAK2-IN-13	JAK STAT	Cancer
JAK2-IN-13 is a potent and orally active JAK2 inhibitor with an IC₅₀ of 54.7 nM. JAK2-IN-13 downregulates the expression of p-STAT3 and p-STAT5. JAK2-IN-13 exhibits good bioavailability and potent inhibition of rhEPO-induced extramedullary erythropoiesis and polycythemia vera. JAK2-IN-13 can be used for the study of myeloproliferative neoplasms .

HY-16398R

Pipobroman (Standard)	DNA Alkylator/Crosslinker DNA/RNA Synthesis	Cancer
Pipobroman (Standard) is the analytical standard of Pipobroman. This product is intended for research and analytical applications. Pipobroman is a bromide derivative of piperazine and acts as an alkylating agent. Pipobroman plays its role by inhibiting DNA and RNA polymerase or by reducing pyrimidine nucleotide incorporation into DNA. Pipobroman can be used for the cancer research, including polycythemia vera, myeloproliferative neoplasm, and AML et.al .

HY-174428

PROTAC JAK2 degrader-1	JAK STAT	Cancer
PROTAC JAK2 degrader-1 (Compound 10i) is a JAK2 PROTAC degrader with a DC₅₀ of 27.35 nM for JAK2 V617F. PROTAC JAK2 degrader-1 promotes the ubiquitination and degradation of JAK2. PROTAC JAK2 degrader-1 inhibits the phosphorylation of JAK2, STAT3 and STAT5. PROTAC JAK2 degrader-1 can be used in the research of myeloproliferative neoplasms (Pink: JAK2 ligand (HY-174430); Blue: E3 ligase ligand (HY-W087383); Black: E3 ligase ligand + linker (HY-174432)) .

HY-P9978

Toripalimab	PD-1/PD-L1	Cancer
Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .

HY-126573R

Trilaurin (Standard)	Reference Standards Others	Cancer
Trilaurin (Standard) is the analytical standard of Trilaurin. This product is intended for research and analytical applications. Trilaurin could inhibit the formation of neoplasms initiated by dimethylbenzanthracene (DMBA) and promoted by croton oil .

HY-P1828

EGFRvIII peptide (PEPvIII)	EGFR	Cancer
EGFRvIII peptide (PEPvIII) is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide represents a truly tumor-specific target for antitumor immunotherapy .

HY-P1828A

EGFRvIII peptide (PEPvIII) TFA	EGFR	Cancer
EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy .

HY-B0139

Flucytosine 3 Publications Verification 5-Fluorocytosine; NSC 103805; Ro 2-9915	Fungal Antibiotic	Infection Cancer
Flucytosine (5-Fluorocytosine) is an antifungal compound with oral activity. Flucytosine is a widely used cytotoxic drug that, after further metabolism, produces fluorinated ribonucleotides and deoxyribonucleotides, inhibits DNA and protein synthesis, and has multiple effects such as inhibiting candida and candida neoplasm infection and producies cytotoxicity to cancer cells .

HY-P99234

Pivekimab	Interleukin Related ADC Antibody	Cancer
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .

HY-B0139R

Flucytosine (Standard) 5-Fluorocytosine (Standard); NSC 103805 (Standard); Ro 2-9915 (Standard)	Reference Standards Fungal Antibiotic	Infection Cancer
Flucytosine (Standard) is the analytical standard of Flucytosine. This product is intended for research and analytical applications. Flucytosine (5-Fluorocytosine) is an antifungal compound with oral activity. Flucytosine is a widely used cytotoxic drug that, after further metabolism, produces fluorinated ribonucleotides and deoxyribonucleotides, inhibits DNA and protein synthesis, and has multiple effects such as inhibiting candida and candida neoplasm infection and producies cytotoxicity to cancer cells .

HY-P991621

EOS006215 EOS-215	TREM receptor	Cancer
EOS006215 is a humanized monoclonal antibody inhibitor targeting TREM-2. EOS006215 reprograms TREM2 ⁺ macrophages, significantly blocks their pleiotropic pro-tumoral functions and overcomes resistance. EOS215 decreases metastasis burden in orthotopic 4T1 triple negative breast cancer mice model and significantly inhibits tumor growth in anti-PD-1 resistant mice model. EOS006215 can be used to study advanced malignant solid neoplasm, such as triple negative breast cancer (TNBC) .

Cat. No.	Product Name

HY-L184

Anti-Gastric Cancer Compound Library	883 compounds
Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer. MCE designs a unique collection of 883 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

Anti-Gastric Cancer Compound Library

883 compounds

Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer.

MCE designs a unique collection of 883 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

HY-L025

Anti-Cancer Compound Library	9,394 compounds
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc. MCE designs a unique collection of 9,394 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.

Anti-Cancer Compound Library

9,394 compounds

Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc.

MCE designs a unique collection of 9,394 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.

Cat. No.	Product Name	Target	Research Area

HY-P1828A

EGFRvIII peptide (PEPvIII) TFA	EGFR	Cancer
EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy .

HY-P1828

EGFRvIII peptide (PEPvIII)	EGFR	Cancer
EGFRvIII peptide (PEPvIII) is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide represents a truly tumor-specific target for antitumor immunotherapy .

Cat. No.	Product Name

HY-K6125

*Human Neuroendocrine Neoplasm* Organoid Kit**
MCE Human Neuroendocrine Neoplasm Organoid Kit includes a basic culture medium for Neuroendocrine Neoplasm organoids, as well as culture supplements, and is designed for the effective construction of human Neuroendocrine Neoplasm organoids.

Cat. No.	Product Name	Target	Research Area

HY-P9978

Toripalimab	PD-1/PD-L1	Cancer
Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .

HY-P99234

Pivekimab	Interleukin Related ADC Antibody	Cancer
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .

HY-P99348

Ropeginterferon alfa-2b Ropeginterferon alfa-2b-njft; PEG-proline-interferon alpha-2b	Apoptosis	Cancer
Ropeginterferon alfa-2b (Ropeginterferon alfa-2b-njft) is a monopegylated IFN-α that can be used for the research of myeloproliferative neoplasms .

HY-P991621

EOS006215 EOS-215	TREM receptor	Cancer
EOS006215 is a humanized monoclonal antibody inhibitor targeting TREM-2. EOS006215 reprograms TREM2 ⁺ macrophages, significantly blocks their pleiotropic pro-tumoral functions and overcomes resistance. EOS215 decreases metastasis burden in orthotopic 4T1 triple negative breast cancer mice model and significantly inhibits tumor growth in anti-PD-1 resistant mice model. EOS006215 can be used to study advanced malignant solid neoplasm, such as triple negative breast cancer (TNBC) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-126573

Trilaurin	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
Trilaurin could inhibit the formation of neoplasms initiated by dimethylbenzanthracene (DMBA) and promoted by croton oil .

HY-126573R

Trilaurin (Standard)	Structural Classification Natural Products Classification of Application Fields Source classification Plants Lauraceae Neolitsea aciculata Disease Research Fields Cancer	Reference Standards Others
Trilaurin (Standard) is the analytical standard of Trilaurin. This product is intended for research and analytical applications. Trilaurin could inhibit the formation of neoplasms initiated by dimethylbenzanthracene (DMBA) and promoted by croton oil .

Cat. No.	Product Name		Classification

HY-126573

Trilaurin		Fillers
Trilaurin could inhibit the formation of neoplasms initiated by dimethylbenzanthracene (DMBA) and promoted by croton oil .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Oligonucleotides

neoplasm

Inhibitors & Agonists

Screening Libraries

Peptides

MCE Kits

Inhibitory Antibodies

NaturalProducts

Oligonucleotides

Natural
Products